Form 4: IO Biotech Director Heidi Hunter Boosts Stake with 15,000 Share Purchase

IO Biotech, Inc. Director Heidi Hunter has acquired 15,000 shares of the company's common stock through a pre-planned transaction, signaling increased insider confidence.

Summary

• Heidi Hunter, a Director of IO Biotech, Inc. (IOBT), purchased 15,000 shares of the company's common stock.
• The transaction occurred on May 30, 2025, at a weighted average price of $1.3923 per share.
• The purchase was executed in multiple trades with prices ranging from $1.37 to $1.40.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Heidi Hunter directly beneficially owns 15,000 shares of IO Biotech, Inc. common stock.

Sentiment

Score: 8

Explanation: The purchase of 15,000 shares by a director, Heidi Hunter, signals strong insider confidence in the company's prospects. While executed under a pre-planned Rule 10b5-1(c) arrangement, it still represents a direct investment by a key insider, which is a positive signal for investors.

Positives

• A director, Heidi Hunter, increased her direct ownership in IO Biotech by purchasing 15,000 shares, indicating strong insider confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-meditated investment strategy rather than a reactive market decision.

Future Outlook

The document does not contain explicit forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the implicit confidence signaled by the insider purchase.

Industry Context

This insider purchase by a director of IO Biotech, a biotechnology company, aligns with a general trend where insider transactions can provide insights into management's perception of a company's value, particularly in sectors like biotech where future pipeline success is critical.

Related Party Transactions

• Heidi Hunter, a director of IO Biotech, Inc., purchased 15,000 shares of the company's common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The insider purchase by a director may instill greater confidence among existing and potential shareholders, suggesting that management believes the stock is undervalued or has significant upside potential.

Key Dates

Recommendation

Keywords

IO Biotech, IOBT, Heidi Hunter, Director, Insider Trading, Form 4, Stock Purchase, Beneficial Ownership, Rule 10b5-1, Biotechnology